Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring V600E Mutation

• Ngā kaituhi matua: Jeong-Hwa Kwon (Author), Byung-Kwan Jeong (Author), Yong Sik Yoon (Author), Chang Sik Yu (Author), Jihun Kim (Author)
• Hōputu: Pukapuka
• I whakaputaina: Korean Society of Pathologists & the Korean Society for Cytopathology, 2018-05-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Background BRAF mutation has been recognized as an important biomarker of colorectal cancer (CRC) for targeted therapy and prognosis prediction. However, sequencing for every CRC case is not cost-effective. An antibody specific for BRAF V600E mutant protein has been introduced, and we thus examined...